METTL3, as a methyltransferase, exhibits oncogenic properties by depositing m6A modifications on critical transcripts, promoting the development and progression of various cancers, including hematologic malignancies and solid tumors, and holds potential for cancer therapy [10]. Here, METTL3 is linked to hematologic disorder.